The Inventor of Ozempic Is Suddenly Sacking Huge Numbers of Employees

Novo Nordisk, the 102-year-old Danish drug maker behind amazing drugs Ozimbek and Wigvical, drops thousands of workers as they seek to recover some revenues that he lost to competitors amid the GLP-1 boom.

In a press release, the giant pharmaceutical company announced that it will soon be abandoned 11 percent of the workforce, which total about 9,000 of its 78,400 employees worldwide. Novo explained that about 5,000 of these discounts will be held in Denmark while it is initiated by a “transformation at the level of the company” to provide about $ 1.3 billion by the end of 2026.

Less than a month ago, Novo admitted Reuters It has carried out “freezing recruitment in critical, non -commercial areas”. Although the company did not explain the decision, the freezing news came a few weeks after one of the news that emerges in the market: issuing a profit warning at the end of July, which warned the stock market that the company’s profit margins were less than expected, and the naming of the new CEO, MAZIAR MIKE DUSTDAR.

The two events were deposited by Novo shares, which decreased by 21 percent, to a little less than $ 47, at the beginning of August; She has since regained $ 54.18, but this is still low from his highest level at this time last year by more than $ 136 per share, or his highest level ever at $ 142 in June 2024.

Beautiful printing behind this advertisement, such as New York Times Other outlets indicate that it revolves around the share of the company that shrinks from the GLP-1 Glp-1 Glp-1, which is a new category of injection by OzemPIC and her sister’s sister drugs, which mimics the feeling of the stomach.

Although OzemPIC is still synonymous with all GLP-1 in general, the competition from Eli Lilly, an American drug company that makes diabetes syringe Mountjaro and its obese counterpart Zepbound, narrowed the Novo market. Certainly, Lilly does not help discounts on Zepbound, which is used like mounjaro active ingredient Tirzepatide, for those who want to fill their doses themselves; Also, the guaranteed pharmacies, which are not organized by their nature, were now selling the issues of a much cheaper gray market than Semaglutide, the active ingredient in OzemPIC and Wegovy.

In the press release of DouStdar, the new CEO, indirectly approved the competition facing the company.

“Our markets are developing, especially in obesity, because they have become more competitive and competing with the consumer,” said CEO. “Our company must also develop.”

Like most executives who demobilize workers, DouStdar display crocodile tears for the workers who finish them, while celebrating money will save with them.

“It is always difficult to see talented and later colleagues who go, but we are convinced that this is the right thing to do for long -term success of Noveau Nordsek,” he said. “We need to turn into a mentality and our approach so that we can be faster and more flexible.”

Just one day after the announcement of job discounts, CEO told the employees that at the beginning of 2026, they must all work full-time-although as a NOVO spokesman told a spokesman. Pharma’s fierceIndividual employees and managers can make alternative arrangements if necessary.

“This has been designed to enhance a stronger feeling of belonging, enhance relations, enhance cooperation and accelerate decision -making operations,” Spox said in their statement.

As of now, it is not clear how demanding that return to the office will help reduce the final result of the Novo. If you really want to retrieve some of the money she lost, the Danish pharmaceutical maker can continue to reduce the price of OzemPIC and Wegovy-which now costs about $ 500 a month for those who do not have insurance, a decrease from $ 1,000 until recently-and put it on an equal footing with China, where the cost of one offer is $ 100, and can be obtained per hour.

More about OzemPIC: Scientists find evidence that OzemPIC can reflect aging